Author: Kevin Grogan

AstraZeneca has linked up with MAP Pharmaceuticals to develop and commercialise the latter’s nebulised formulation of budesonide, the active ingredient found in the drug giant’s asthma treatment Pulmicort.

GlaxoSmithKline says it is ready to up its supply of the flu drug Relenza in the USA after health officials warned that a strain of influenza circulating in the country this winter is resistant to Roche’s rival drug Tamiflu.

Forest Laboratories has signed a deal with France’s Pierre Fabre which gives it North American rights to develop and commercialise the antidepressant F2695.

Amgen has filed its eagerly-anticipated investigational osteoporosis treatment denosumab with US regulators.

Christmas is coming but there is no let-up at GlaxoSmithKline which is ending all political contributions, buying Bristol-Myers Squibb’s Pakistan operations, extending a pact with Galapagos and reporting positive data for a drug seen as the follow-up to Advair.